Table 1.

Demographic and clinical characteristics of early stage multiple sclerosis subjects and healthy controls

	Multiple sclerosis subjects	Healthy controls
Gender, n (females/males)	26 (21/5)	24 (17/7)†
Age, years, mean ± SD	39.0 ± 8.2	37.7 ± 10.6‡
Disease duration, years, mean ± SD	2.5 ± 1.4	-
EDSS scores, median (range)	1.5 (0–4)	-
Disease-modifying treatments (n)	Dimethyl fumarate (n = 11)
	Glatiramer acetate (n = 6)
	Interferon beta-1a (n = 4)
	Natalizumab (n = 1)
	None (n = 4)

^†P = 0.51 versus multiple sclerosis subjects by Fischer’s exact test.

^‡P = 0.64 versus multiple sclerosis subjects by unpaired t-test.

SD = standard deviation.